Geoffrey I. Shapiro
Broad Institute(US)Boston University(US)Brigham and Women's Hospital(US)Harvard University(US)Dana-Farber Cancer Institute(US)Dana-Farber/Harvard Cancer Center(US)Center for Cancer Research(US)Dana-Farber Brigham Cancer Center(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, PARP inhibition in cancer therapy, Pancreatic and Hepatic Oncology Research, Advanced Breast Cancer Therapies
Most-Cited Works
- → Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer(2010)4,491 cited
- → Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer(2014)1,981 cited
- → KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors(2020)1,646 cited
- → BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models(2008)1,434 cited
- → Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study(2012)1,275 cited
- → Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors(2013)1,232 cited